Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
14.1M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
3.71M
-
Shares change
-
-111K
-
Total reported value, excl. options
-
$11M
-
Value change
-
-$328K
-
Number of buys
-
6
-
Number of sells
-
-5
-
Price
-
$2.98
Significant Holders of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) as of Q3 2025
22 filings reported holding GRCE - Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2025.
Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.71M shares
of 14.1M outstanding shares and own 26.37% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (1.18M shares), AIGH Capital Management LLC (907K shares), BANK OF AMERICA CORP /DE/ (495K shares), VANGUARD GROUP INC (409K shares), ADAR1 Capital Management, LLC (350K shares), Stonepine Capital Management, LLC (211K shares), RENAISSANCE TECHNOLOGIES LLC (84.6K shares), CITADEL ADVISORS LLC (27.3K shares), Millington Financial Advisors, LLC (20K shares), and SeaCrest Wealth Management, LLC (14K shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.